ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Medicare Cuts Could Limit Access to Critical Lab Tests

By: NewsUSA

(NewsUSA) - Medical tests done by clinical laboratories are an essential part of health care. However, repeated Medicare reimbursement cuts to clinical laboratory services could threaten patients’ access to common tests used to diagnose, monitor and manage serious diseases such as cancer, diabetes and heart disease.     

A new campaign, called Stop Lab Cuts, is working to fix this problem and is urging Congress to pass the Saving Access to Laboratory Services Act (SALSA) this year.     

SALSA is intended to reform the Protecting Access to Medicare Act (PAMA) passed by Congress in 2014, which has led to three rounds of payment cuts to laboratory services since the law was enacted.     

PAMA put Medicare reimbursement for clinical laboratory tests on an unsustainable path of multiyear cuts and relied on a narrow sample of clinical laboratory test prices to set Medicare rates, according to the American Clinical Laboratory Association (ACLA), the national trade organization representing clinical laboratories that provide diagnostic services across the United States.     

Congress has acknowledged the potentially harmful effects of PAMA and has taken bipartisan legislative action three times to delay cuts. Now, on the cusp of the next scheduled round of cuts, SALSA has been introduced to reform PAMA and protect access to laboratory tests, according to ACLA.     

SALSA has support from both parties in the House and Senate and from patient, provider and hospital groups.     

“Without congressional action this year, laboratories across the country will face a fourth round of cuts to reimbursement. These cuts could reduce access to testing and undermine the laboratory infrastructure essential for day-to-day care and needed to respond to emergencies such as COVID-19 and monkeypox. Ongoing cuts to payment will also stifle innovation and investment in new screening and diagnostic tests,” ACLA leadership said in a statement.   

Reforms proposed in SALSA include:     

  • Ensuring that representative data is used in Clinical Laboratory Fee Schedule (CLFS) rates and alleviating the reporting burden on labs by using statistical sampling.     
  • Setting a limit of 5% on how much a CLFS rate could be increased or decreased from year to year.       
  • Improving the types of private payor data used to set CLFS rates.     
  • Increasing the length of time between data reporting from three years to four years.     

America needs a strong clinical laboratory infrastructure to support the delivery of routine patient care, and passage of SALSA would help protect access to the most common laboratory tests on which so many of America’s seniors depend, according to ACLA. 

Recent Quotes

View More
Symbol Price Change (%)
AMZN  232.39
+3.23 (1.41%)
AAPL  276.52
-1.03 (-0.37%)
AMD  216.26
+2.02 (0.95%)
BAC  53.83
+0.84 (1.59%)
GOOG  319.13
-1.15 (-0.36%)
META  645.30
+11.69 (1.84%)
MSFT  491.00
+5.50 (1.13%)
NVDA  177.06
-3.20 (-1.78%)
ORCL  201.47
-3.49 (-1.70%)
TSLA  429.49
+2.91 (0.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.